Monte Rosa reports Q2 2026 results as MGD pipeline advances on three frontsAug 6Quarterly updateMonte Rosa Therapeutics, Inc
Monte Rosa registers Phase 2 trial pairing MRT-2359 with apalutamide in prostate cancerAug 4Trial updateapalutamideMonte Rosa Therapeutics, Inc
FDA approves labeling supplement for Janssen's Erleada (apalutamide)Jun 29Regulatory decisionapalutamideJohnson & Johnson
Sign inSign in